GERN Geron Corp
Price (delayed)
$1.59
Market cap
$1.01B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.27
Enterprise value
$1.16B
Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The Company currently is conducting two
Highlights
The company's gross profit has surged by 161% QoQ
The revenue has soared by 161% from the previous quarter
Geron's equity has increased by 13% YoY but it has decreased by 4.1% from the previous quarter
GERN's debt has surged by 163% year-on-year and by 159% since the previous quarter
Key stats
What are the main financial stats of GERN
Market
Valuations
Earnings
Shares outstanding
636.9M
Market cap
$1.01B
Enterprise value
$1.16B
Price to earnings (P/E)
N/A
Price to book (P/B)
3.43
Price to sales (P/S)
13.34
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
15.04
Revenue
$76.99M
Gross profit
$75.74M
Operating income
-$173.73M
Net income
-$174.57M
EBIT
-$156.07M
EBITDA
-$154.85M
Free cash flow
-$219.3M
Per share
Balance sheet
Liquidity
EPS
-$0.27
EPS diluted
-$0.27
Free cash flow per share
-$0.34
Book value per share
$0.46
Revenue per share
$0.12
TBVPS
$0.92
Total assets
$593.78M
Total liabilities
$313.46M
Debt
$226.14M
Equity
$280.32M
Working capital
$402.69M
Debt to equity
0.81
Current ratio
5.56
Quick ratio
5.06
Net debt/EBITDA
-0.94
Margins
Efficiency
Dividend
EBITDA margin
-201.1%
Gross margin
98.4%
Net margin
-226.7%
Operating margin
-225.6%
Return on assets
-35.4%
Return on equity
-57%
Return on invested capital
-40.2%
Return on capital employed
-30.9%
Return on sales
-202.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
GERN stock price
How has the Geron stock price performed over time
Intraday
7.43%
1 week
-6.47%
1 month
-9.66%
1 year
-48.71%
YTD
-55.08%
QTD
0%
Financial performance
How have Geron's revenue and profit performed over time
Revenue
$76.99M
Gross profit
$75.74M
Operating income
-$173.73M
Net income
-$174.57M
Gross margin
98.4%
Net margin
-226.7%
The company's gross profit has surged by 161% QoQ
The revenue has soared by 161% from the previous quarter
The operating margin has soared by 100% year-on-year and by 68% since the previous quarter
GERN's net margin has surged by 100% year-on-year and by 67% since the previous quarter
Growth
What is Geron's growth rate over time
Valuation
What is Geron stock price valuation
P/E
N/A
P/B
3.43
P/S
13.34
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
15.04
Geron's EPS has increased by 16% from the previous quarter and by 16% YoY
The P/B is 58% below the last 4 quarters average of 7.6 and 35% below the 5-year quarterly average of 4.9
Geron's equity has increased by 13% YoY but it has decreased by 4.1% from the previous quarter
The revenue has soared by 161% from the previous quarter
The P/S is 99% below the 5-year quarterly average of 1726.3 and 99% below the last 4 quarters average of 1495.2
Efficiency
How efficient is Geron business performance
Geron's ROS has soared by 100% YoY and by 68% from the previous quarter
Geron's ROIC has increased by 36% from the previous quarter and by 25% YoY
The ROA has grown by 22% from the previous quarter and by 21% YoY
GERN's ROE is up by 16% since the previous quarter and by 10% year-on-year
Dividends
What is GERN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for GERN.
Financial health
How did Geron financials performed over time
Geron's total assets is 89% higher than its total liabilities
The total liabilities has soared by 115% year-on-year and by 105% since the previous quarter
GERN's current ratio has soared by 92% since the previous quarter and by 76% year-on-year
GERN's debt is 19% smaller than its equity
GERN's debt to equity has soared by 170% QoQ and by 131% YoY
GERN's debt has surged by 163% year-on-year and by 159% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.